Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer
-
Published:2024-12
Issue:6
Volume:22
Page:102187
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Obasi JenniferORCID,
Sharma Komal,
De Sarkar Navonil,
Antonarakis Emmanuel S.,
Kilari Deepak
Reference38 articles.
1. Homologous recombination in DNA repair and DNA damage tolerance;Li;Cell Res,2008
2. Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors;Miller;OncoTargets and Therapy,2022
3. Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors;Mekonnen;Front Oncol,2022
4. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer;Pritchard;N Eng J Med,2016
5. Integrative clinical genomics of advanced prostate cancer;Robinson;Cell,2015